What's breaking now, across thousands of outlets.
(RTTNews) - Tuesday, Dyne Therapeutics (DYN) reported additional one-year data from the Phase 1/2 ACHIEVE trial showing that zeleciment basivarsen (DYNE-101) improved multiple functional measures in patients with myotonic dystrophy type 1 (DM1).
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
Key PointsA $10,000 stake in Bloom Energy at the end of September 2021 had dropped to under half its value by early 2024.
Key PointsVGT features a significantly lower expense ratio, which can help investors save money on fees.
Chinese lithium futures have shed a quarter of their value this month, pummeled by concerns over flagging demand.
Overseas investors are turning sellers of Indian assets again as surging oil prices and rising global yields threaten to derail a recent revival in demand.
